alexa Cost-effectiveness And Pharmacoeconomic Analysis Of Combined Inhaled Corticosteroids And Brochodilators For Severe And Very Severe COPD Patients And Health Related Quality Of Life Of COPD Patients In A Teaching Hospital
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Mohammed Altaf, Shaik Kareemulla, Ayesha Mubeen Zubedi, Fareesa Nazneen, Syed Aamir Ali and Mohammed Aleemuddin Naveed
Posters: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.014
Abstract
Background: This study aims at simplifying the practical patient management and offers some general indications for pharmacotherapeutic choice by the implementation of (GOLD 2004) guidelines. This study was designed to evaluate the clinical and economic consequences of Salmeterol/Fluticasone, Formoterol/Budesonide and Formoterol/Fluticasone in severe and very severe COPD patients. Objectives: To find out the most cost-effective drug combination between the three combinations (SF/FB/FF) in COPD patients and Health Related Quality of Life of COPD Patients. Methods: A prospective observational comparative study (Cost-effectiveness Analysis) in which 90 severe (30≤FEV1<50% predicted) and very severe (FEV1<30% predicted) COPD patients (OP/IP) who are prescribed with any one of the following combinations (SF/FB/FF) were selected. In our study we have divided 90 COPD patients into 3 groups (Group I, Group II & Group III) each group consisting of 30 patients. Group I was prescribed with medication SF (salmeterol/fluticasone), Group II with medication FB (formoterol/budesonide) and Group III with medication FF (formoterol/fluticasone). We used five different parameters such as Spirometry test (mean FEV1 initial & final visit), SGRQ-C questionnaire (initial & final visit), number of symptom free days, number of moderate & severe exacerbations and direct, indirect & total cost to assess the costeffectiveness of SF/FB/FF. Comparison of cost and effects was done during the period of 6 months of using SF/FB/FF. Statistical methods used in our study are paired student t-test, ANOVA. Results: The mean SGRQ-C total score for group I subjects (SF) at initial visit was 86.69 and the scores reduced to 58.78 at final visit (i.e. after using SF for 6 months). This reduction was highly significant statistically (t=10.989, p=0.000) at 95% CI. The mean SGRQ-C total scores for group II subjects (FB) at initial visit were 85.85 and the scores reduced to 67.98 at final visit. This reduction was highly significant statistically (t=9.669, p=0.000) at 95% CI. The mean SGRQ-C total scores for group III subjects (FF) at initial visit were 83.96 and the scores reduced to 70.37 at final visit (after 6 months). This reduction was highly significant statistically (t=12.285, p=0.000) at 95% CI. The average FEV1 for group I, group II and group III subjects at initial visit was 33.47%, 33.73% & 33.20% and was increased to 36.60%, 35.8% and 33.4% respectively. A 3% increment in FEV1 was reported for group I subjects (SF) and was highly significant statistically (t=-8.833, p=0.000) at 95% CI. For group II subjects (FB), a 2% increment in FEV1 was reported and was highly significant statistically (t=-9.001, p=0.000) at 95% CI. For group III subjects 0.2% increment in FEV1. The overall mean total cost for groupI, groupII and groupIII subjects during the 6 months period was found to be Rs.29725/-, Rs.32602/- and Rs.37155/-. Incremental cost-effectiveness of FB vs SF was Rs.37781/- per avoided exacerbation and Rs.661/- per SFD. Conclusion: This study highlighted the favorable therapeutic performance of combined inhaled bronchodilators & corticosteroids (SF/FB/FF), thus suggesting that healthcare costs would be also affected positively. Results from our study showed that SF (Salmeterol/Fluticasone) and FB (Formoterol/Budesonide)) were the most effective strategies in the treatment of COPD, with a slight clinical superiority of SF. The FF (Formoterol/Fluticasone) strategy was not much effective (i.e. associated with less outcomes & higher costs).
Biography
Mohammed Altaf, pursuing his Pharm.D from Deccan School of Pharmacy affiliated to Jawaharlal Nehru Technological University, Hyderabad, Telangana, India. He is doing his internship from Owaisi Hospital and Research Centre-Hyderabad, Telangana, India. He had published 4 Original Research papers in National and International journals and has been serving as reviewer of International Journal of Pharmacy and Pharmaceutical Sciences. He is also the Junior Editor of Clini Pharma ?Insight?.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version